Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer
复制标题
DOI：
10.1007/s12032-014-0856-0
复制
发表时间：
2014-03-01
期刊：
影响因子：
3.4
通讯作者：
Baba, Eishi
中科院分区：
文献类型：
--
作者：
Tamura, Shingo;Kusaba, Hitoshi;Baba, Eishi
贝伐珠单抗是一种广泛用于治疗结直肠癌的药物。虽然它与多种不良事件有关，但据报道，在晚期结直肠癌基于贝伐珠单抗的化疗中，有几例药物引起的间质性肺损伤。在这项研究中，我们回顾性回顾了连续 72 名接受贝伐单抗化疗的晚期结直肠癌患者，并确定了 5 例 (6.9%) 出现间质性肺炎 (IP)。中位年龄为 68 岁，五名患者均为男性，五名患者中有四名吸烟者。 3例无症状，停化疗后立即康复。另一方面，两例重症病例需要输注大剂量皮质类固醇。建议早期诊断 IP 有助于防止事件恶化并获得更好的结果。 IP可能与全身化疗有关，这表明应警惕基于贝伐珠单抗的化疗对肺部的损害。
Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9 %) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.